Abstract:Candida auris has globally emerged as a multidrug-resistant fungus linked to healthcare-associated outbreaks. There is still limited evidence on its virulence, pathogenicity determinants, and complex host-pathogen interactions. This study analyzes the in vivo fungal behaviour, immune response, and host-pathogen interactions upon C. auris infection compared to C. albicans and C. parapsilosis in G. mellonella. This was performed by immunolabelling fungal structures and larval plasmatocytes and using a quantitative approach incorporating bioinformatic morphometric techniques into the study of microbial pathogenesis. C. auris presents a remarkably higher immunogenic activity than expected at its moderate degree of tissue invasion. It induces a greater inflammatory response than C. albicans and C. parapsilosis at the expense of plasmatocyte nodule formation, especially in non-aggregative strains. It specifically invades the larval respiratory system, in a pattern not previously observed in other Candida species, and presents inter-phenotypic tissue tropism differences. C. auris filaments in vivo less frequently than C. albicans or C. parapsilosis mostly through pseudohyphal growth. Filamentation might not be a major pathogenic determinant in C. auris, as less virulent aggregative phenotypes form pseudohyphae to a greater extent. C. auris has important both interspecific and intraspecific virulence and phenotype heterogeneity, with aggregative phenotypes of C. auris sharing characteristics with low pathogenic species such as C. parapsilosis. Our work suggests that C. auris owns an important morphogenetic plasticity that distinguishes it from other yeasts of the genus. Routine phenotypic identification of aggregative or non-aggregative phenotypes should be performed in the clinical setting as it may impact patient management.

The sphingolipid inhibitor myriocin increases Candida auris susceptibility to amphotericin B

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales

Synergistic Effect of Essential Oils and Antifungal Agents in Fighting Resistant Clinical Isolates of Candida auris

Potential Activity of Micafungin and Amphotericin B Co-Encapsulated in Nanoemulsion against Systemic Candida auris Infection in a Mice Model

Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model

Amphotericin B and micafungin duo-loaded nanoemulsion as a potential strategy against Candida auris biofilms

Rare modification in the ergosterol biosynthesis pathway leads to amphotericin B resistance in Candida auris clinical isolates

Improved efficacy of antifungal drugs in combination with monoterpene phenols against Candida auris

Exploring synergy between azole antifungal drugs and statins for Candida auris

Exploring the antifungal potential of novel carbazate derivatives as promising drug candidates against emerging superbug, Candida auris

Effect of Myrtenol and Its Synergistic Interactions with Antimicrobial Drugs in the Inhibition of Single and Mixed Biofilms of Candida auris and Klebsiella pneumoniae

Alteration of β-glucan in the emerging fungal pathogen Candida auris leads to immune evasion and increased virulence

Host–pathogen interactions upon Candida auris infection: fungal behaviour and immune response in Galleria mellonella

Genetic microevolution of clinical Candida auris with reduced Amphotericin B sensitivity in China

Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant Candida auris

Antifungal Activity of Select Essential Oils against Candida auris and Their Interactions with Antifungal Drugs

Small molecule inhibitors of fungal Δ(9) fatty acid desaturase as antifungal agents against Candida auris

Innate immune responses against the fungal pathogen Candida auris

Enhancedin Vitroantimicrobial Activity Of Amphotericin B With Berberine Against Dual-Species Biofilms Ofcandida Albicansandstaphylococcus Aureus

Antibiofilm activity of truncated Staphylococcus aureus phenol soluble modulin α2 (SaΔ1Δ2PSMα2) against Candida auris in vitro and in an animal model of catheter-associated infection